AU5187190A - Improved baculovirus expression system capable of producing foreign gene proteins at high levels - Google Patents

Improved baculovirus expression system capable of producing foreign gene proteins at high levels

Info

Publication number
AU5187190A
AU5187190A AU51871/90A AU5187190A AU5187190A AU 5187190 A AU5187190 A AU 5187190A AU 51871/90 A AU51871/90 A AU 51871/90A AU 5187190 A AU5187190 A AU 5187190A AU 5187190 A AU5187190 A AU 5187190A
Authority
AU
Australia
Prior art keywords
high levels
system capable
expression system
foreign gene
baculovirus expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51871/90A
Inventor
C. Yong Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Ottawa
Original Assignee
University of Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA000591908A external-priority patent/CA1330425C/en
Priority claimed from US07/316,768 external-priority patent/US5194376A/en
Application filed by University of Ottawa filed Critical University of Ottawa
Publication of AU5187190A publication Critical patent/AU5187190A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU51871/90A 1989-02-23 1990-02-23 Improved baculovirus expression system capable of producing foreign gene proteins at high levels Abandoned AU5187190A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA591908 1989-02-23
CA000591908A CA1330425C (en) 1989-02-23 1989-02-23 Baculovirus expression system capable of producing foreign gene proteins at high levels
US07/316,768 US5194376A (en) 1989-02-28 1989-02-28 Baculovirus expression system capable of producing foreign gene proteins at high levels
US316768 1989-02-28

Publications (1)

Publication Number Publication Date
AU5187190A true AU5187190A (en) 1990-09-26

Family

ID=25672469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51871/90A Abandoned AU5187190A (en) 1989-02-23 1990-02-23 Improved baculovirus expression system capable of producing foreign gene proteins at high levels

Country Status (2)

Country Link
AU (1) AU5187190A (en)
WO (1) WO1990010078A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631223B2 (en) * 1989-05-17 1992-11-19 University Of Georgia Research Foundation, Inc., The Improved baculovirus expression vectors

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
CA2590462C (en) 2004-12-22 2017-02-28 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
BRPI0519170A8 (en) 2004-12-22 2018-05-08 Ambrx Inc human growth hormone formulations comprising an unnaturally encoded amino acid
EP2284191A3 (en) 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
SG158186A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN101247821B (en) 2005-06-03 2013-01-23 Ambrx公司 Improved human interferon molecules and their uses
KR20080079643A (en) 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 Methods and compositions comprising non-natural amino acids
CA2662753C (en) 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
MX2009002523A (en) 2006-09-08 2009-03-20 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their uses.
WO2008030614A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
ATE554785T1 (en) 2007-03-30 2012-05-15 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
KR101656107B1 (en) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 Modified insulin polypeptides and their uses
MX344166B (en) 2008-02-08 2016-12-07 Ambrx Inc Modified leptin polypeptides and their uses.
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
NZ607477A (en) 2008-09-26 2014-09-26 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
EP3216800A1 (en) 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
SI3412302T1 (en) 2014-10-24 2021-09-30 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631223B2 (en) * 1989-05-17 1992-11-19 University Of Georgia Research Foundation, Inc., The Improved baculovirus expression vectors

Also Published As

Publication number Publication date
WO1990010078A1 (en) 1990-09-07

Similar Documents

Publication Publication Date Title
AU5187190A (en) Improved baculovirus expression system capable of producing foreign gene proteins at high levels
AU7469787A (en) Process for the genetic modification of yeast
AU6844290A (en) Implant having varying modulus of elasticity
AU6053090A (en) Manufacture of carbon fibre preform
IL96765A0 (en) Modification of the expression characteristics of an endogenous gene
AU7984287A (en) Proteins of aids envelope gene
AU1482488A (en) Leader sequences for the production of recombinant proteins
AU7239587A (en) Novel thrombolytic proteins
AU7831787A (en) Improved recombinant expression
AU6067190A (en) Improved stable coagulation controls
AU3468689A (en) Process for the preparation of dideoxycytidine
AU2885489A (en) Enzymatic hydrolysis of proteins
AU626147B2 (en) Fibrinolytic proteins
AU1406497A (en) Mutational variants of mammalian ob gene proteins
AU627565B2 (en) Process for the preparation of cefodizime sodium
AU7312787A (en) Improved tandem-axle walking beam suspension
AU623837B2 (en) Process for decantation of suspensions
AU4731389A (en) Suspension adjustment
AU5759190A (en) Protein hydrolysis
AU5567090A (en) Purification of proteins employing ctap-iii fusions
AU2710388A (en) Acceleration of bone formation with gm-csf
AU5390294A (en) Biologically active synthetic thyrotropin and cloned gene for producing same
AU625234B2 (en) Stabilization of glycosylized t-pa
GB8904426D0 (en) Improved baculovirus expression system capable of producing foreign gene proteins at high levels
AU6603090A (en) Enzymatic production of d-amino acids